NCT04693767 (INSIGHT) is a clinical trial of Mechanical thrombectomy in Ischemic Stroke, sponsored by Penumbra Inc..

Who is sponsoring NCT04693767?

NCT04693767 is sponsored by Penumbra Inc..

What drugs are being tested in NCT04693767?

Interventions in NCT04693767: Mechanical thrombectomy, Minimally invasive surgery.

What condition does NCT04693767 study?

NCT04693767 studies Ischemic Stroke, Intracranial Hematoma.

Is NCT04693767 still recruiting?

NCT04693767 is currently completed. Last updated 23 October 2024.

Are results published for NCT04693767?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-10-23 · How we verify

NCT04693767: INSIGHT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Investigation of Clot in Ischemic Stroke and Hematoma Evacuation

Completed Results posted Last updated 23 October 2024

What this trial tests

trial testing Mechanical thrombectomy in Ischemic Stroke in 400 participants. Completed in 3 August 2022.

Timeline

16 February 2021

Primary endpoint
22 July 2022

3 August 2022

Quick facts

Lead sponsor	Penumbra Inc.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	400
Start date	16 February 2021
Primary completion	22 July 2022
Estimated completion	3 August 2022
Sites	27 locations across United States

Drugs / interventions tested

Mechanical thrombectomy — full drug profile →
Minimally invasive surgery

Conditions studied

Ischemic Stroke — all drugs for Ischemic Stroke →
Intracranial Hematoma — all drugs for Intracranial Hematoma →

Sponsor

Penumbra Inc. — full company profile →

Who can join

18 and older, any sex, with Ischemic Stroke or Intracranial Hematoma. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Clot Specimen Histology Primary · Clot specimen obtained during procedure

Numbers of clot specimen for histology analysis

Group	Value	95% CI
Patients With Ischemic Stroke	373
Patients With Intracranial Hematoma	12

Blood and Clot Specimen Transcriptomics Primary · Blood and clot specimen obtained during procedure

Numbers of blood and clot for RNA sequency. Only includes successful sample number that was processed.

Clot RNA Analyzed

Group	Value	95% CI
Patients With Ischemic Stroke	341
Patients With Intracranial Hematoma	9

Blood RNA Analyzed

Group	Value	95% CI
Patients With Ischemic Stroke	365
Patients With Intracranial Hematoma	12

Blood and Clot Specimen Proteomics Primary · Blood and clot specimen obtained during procedure

Numbers of blood and clot specimen for proteomic analysis

Clot Protein Analysis

Group	Value	95% CI
Patients With Ischemic Stroke	351
Patients With Intracranial Hematoma	12

Blood Protein Analysis

Group	Value	95% CI
Patients With Ischemic Stroke	366
Patients With Intracranial Hematoma	12

Blood and Clot Specimen Genomics Primary · Blood and clot specimen obtained during procedure

Numbers of blood and clot specimen for single nucleotide polymorphisms (SNPs). Only includes successful sample number that was processed.

Group	Value	95% CI
Patients With Ischemic Stroke	387
Patients With Intracranial Hematoma	12

Adverse events — posted to ClinicalTrials.gov

Time frame: Adverse events were collected through 7 days post-procedure.. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Patients With Ischemic Stroke

Serious: 38/165 (23%)

Deaths: 86/388

Patients With Intracranial Hematoma

Serious: 0

Deaths: 3/12

Serious adverse events (7 terms)

Reaction	System	Patients With Ischemic Str…	Patients With Intracranial…
Progression of Index Stroke	Nervous system disorders	—	—
Other	Investigations	—	—
Acute Ischemic Stroke	Nervous system disorders	—	—
Pneumonia	Infections and infestations	—	—
Symptomatic ICH	Nervous system disorders	—	—
New or Worsening Neurological Deficit	Nervous system disorders	—	—
Hemorrhagic Stroke	Nervous system disorders	—	—

Other adverse events (4 terms — click to expand)

Reaction	System	Patients With Ischemic Str…	Patients With Intracranial…
Asymptomatic ICH	Nervous system disorders	—	—
Progression of Index Stroke	Nervous system disorders	—	—
Asymptomatic Petechial Hemorrhage	Nervous system disorders	—	—
Anemia	Blood and lymphatic system disorders	—	—

Most-reported serious reactions: Progression of Index Stroke, Other, Acute Ischemic Stroke, Pneumonia, Symptomatic ICH, New or Worsening Neurological Deficit, Hemorrhagic Stroke.

Data from ClinicalTrials.gov NCT04693767 adverse events section.

Sponsor's own description

The aim of the study is to collect and analyze specimen from ischemic stroke patients undergoing thrombectomy procedures and from patients undergoing minimally invasive surgery for intracranial hematoma evacuation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Using clinical and thrombus characteristics to predict the etiology of ischemic stroke: An analysis of the INSIGHT registry.
Branscom GA, Seah C, Som T, Vicari J, et al · · 2026 · PMID 42155823 · DOI 10.1016/j.jstrokecerebrovasdis.2026.108665

Verify or expand the search:

Other trials of Mechanical thrombectomy

Trials testing the same drug.

NCT06964724 — NeVa Retrospective Comparative SR Study · active not recruiting
NCT06758609 — To Assess the Effectiveness and Safety of Catheter-based Focal Intracranial Hypothermia Combined with Endovascular Reper · NA · recruiting
NCT06560203 — Basilar Artery Occlusion Chinese Endovascular Trial in the Extended Time Window · NA · recruiting
NCT06187987 — Mechanical Thrombectomy With the FlowTriever Device in Acute Pulmonary Embolism - a Retrospective Analysis · completed
NCT05719688 — Evaluate the Safety and Efficacy of Thrombectomy System in the Intravascular Treatment of Acute Ischemic Stroke · NA · completed

Other recruiting trials for Ischemic Stroke

Currently open trials in the same condition.

NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting

Other Penumbra Inc. trials

Trials by the same sponsor.

NCT06446024 — Post Market Surveillance to Evaluate the Efficacy and Safety of the INDIGO Aspiration System in Japan · completed
NCT05684796 — Comparison of Two Pulmonary Embolism Treatments · NA · completed
NCT05437055 — THUNDER: Acute Ischemic Stroke Study with the Penumbra System® Including Thunderbolt™ Aspiration Tubing · NA · completed
NCT04157270 — LOTUS: Global Acute Stroke Study Utilizing Penumbra System · terminated
NCT04144959 — A Study of Patients With Lower Extremity Acute Limb Ischemia to Remove Thrombus With the Indigo Aspiration System · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04693767 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Penumbra Inc.
Last refreshed: 23 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04693767.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing